6533b82cfe1ef96bd128f3ef

RESEARCH PRODUCT

Effect of tiotropium/olodaterol combination therapy on long-term heart rate and blood pressure in COPD patients

subject

description

Introduction: Cardiovascular (CV) comorbidities are common in COPD, and associated with poor prognosis. LABAs and LAMAs are established COPD treatments whose pharmacology would suggest the potential to increase heart rate (HR) and impact blood pressure (BP). However, previous studies indicate that HR and BP are not negatively influenced by tiotropium (Tio) or olodaterol (Olo) monotherapy. Aims: To determine the effect of dual bronchodilation with Tio/Olo (T/O) on HR and BP. Methods: The 52-week, Phase III TONADO® studies (NCT01431274/NCT01431287) evaluated T/O 5/5 µg, Tio 5 µg or Olo 5 µg, via the Respimat® inhaler, in GOLD 2–4 COPD patients. In this post hoc analysis, long-term changes from baseline in resting HR (using ECGs) and resting BP (whilst sitting) were analysed at weeks 12, 24 and 52 using pre-dose measurements. Results: Over 52 weeks, small changes in mean HR ( Conclusions: There was no indication of an additive effect on HR or BP with combination T/O treatment when compared with Tio or Olo monotherapy. This argues against any clinically relevant negative effects on HR and BP for T/O combination therapy in COPD patients.